Search the Newsreel

Renaissance Technologies LLC Acquires Shares of 63,900 Upbound Group, Inc. $UPBD

Renaissance Technologies LLC has acquired 63,900 shares of Upbound Group, Inc. (NASDAQ:UPBD) for approximately $1.15 million, representing a 0.11% stake in the company. Upbound Group reported strong quarterly earnings, surpassing analyst estimates, and currently offers a high annualized dividend yield of 7.9%. The company …

Truist Financial Maintains UpStream Bio(UPB.US) With Buy Rating, Maintains Target Price $25

Truist Financial has reiterated its Buy rating for UpStream Bio (UPB.US) and maintained its target price at $25. This indicates the firm's continued positive outlook on the company's stock performance.

A Quick Look at Today's Ratings for UpStream Bio(UPB.US), With a Forecast Between $19 to $36

This article provides a quick look at today's analyst ratings for UpStream Bio (UPB.US), noting a forecast price range between $19 and $36. It indicates that these ratings are based on the average price targets set by various financial analysts.

Upstream Bio (UPB) Earnings Date and Reports 2026 $UPB

Upstream Bio (UPB) announced its Q2 2026 earnings on August 11, 2026, reporting an EPS of -$0.73, beating analyst estimates by $0.01. The company also exceeded revenue expectations with $0.77 million against an estimated $0.56 million. Despite beating estimates, Upstream Bio's earnings are projected …

Upstream Bio (NASDAQ:UPB) Announces Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Upstream Bio (NASDAQ:UPB) announced its quarterly earnings, reporting an adjusted loss of $0.73 per share, surpassing analyst expectations of a $0.78 loss by $0.05. The company also exceeded revenue forecasts, reaching $0.77 million against an expected $0.43 million. Despite beating estimates, Upstream Bio remains …

Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates

Upstream Bio posts corporate presentation highlighting verekitug Phase 3 plans in severe asthma, CRSwNP

Upstream Bio has released a corporate presentation detailing its plans for verekitug, a TSLP receptor antagonist, including a mid-2026 FDA meeting and Phase 3 trials in severe asthma and CRSwNP targeting Q1 2027. The company's pipeline shows promising Phase 2 data for verekitug in …

Form 8K Upstream Bio Inc For: 11 August By Investing.com

This article announces that Upstream Bio Inc. has filed a Form 8K on August 11, with its stock symbol UPB showing a 2.22% increase. The content provided is primarily a placeholder for this financial filing, with minimal specific details about the 8K's contents. It …

Upstream Bio, Inc. 2Q 2026: Revenue $0.8M, EPS $(0.73) — 10-Q Summary

Upstream Bio, Inc. reported its second-quarter 2026 results, showing revenue of $0.8M and a net loss of $39.7M, resulting in a diluted EPS of $(0.73), which is largely consistent with the previous year. The company highlighted clinical progress for Verekitug in severe asthma and …

Upstream Bio (UPB) deepens R&D spend but ends quarter with $261M cash

Upstream Bio (NASDAQ: UPB) reports Q2 2026 loss and advances Phase 3 plans

Upstream Bio (NASDAQ: UPB) reported a Q2 2026 net loss of $39.7 million, similar to the previous year, with cash reserves of $261.3 million expected to fund operations through 2027. The company is advancing its lead asset, verekitug, towards Phase 3 trials for severe …

Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress

Upstream Bio announced its second-quarter 2026 financial results, highlighting significant progress in developing verekitug for severe inflammatory respiratory diseases. The company is on track to initiate Phase 3 trials for severe asthma and CRSwNP in Q1 2027 and has completed enrollment for its Phase …

Upbound Group (UPBD) Dropped, So What Is Behind The Latest Move?

Upbound Group (UPBD) recently reported Q2 2026 results, leading to a stock drop of 3.08% over the last day and 9.17% over the past month. Despite the short-term pressure, the stock shows a 10.78% year-to-date return, though long-term performance has been weak. The article …

Should Upbound Group’s (UPBD) Refined 2026 Revenue Guidance Prompt Portfolio Moves From Investors?

Upbound Group (UPBD) reported modestly higher Q2 2026 sales, revenue, and net income, alongside narrowing its full-year 2026 revenue outlook to US$4.70–US$4.85 billion and providing Q3 guidance. This refined guidance offers investors a clearer view of expected performance, with a projected 44% upside to …

Upbound Group, Inc. (UPBD) stock price, news, quote and history

This article provides a comprehensive overview of Upbound Group, Inc. (UPBD), detailing its stock performance, financial data, and business operations. It includes key financial metrics, analyst insights, and comparisons with similar companies in the Software—Application industry. The company, formerly Rent-A-Center, Inc., offers financial solutions …

Upstream Bio Inc (UPB) Earnings Forecast: Future EPS & Revenue Growth Estimates

Upstream Bio Inc (UPB) has an earnings forecast score of 7.78, ranking 268th in the Biotechnology & Medical Research industry. Analysts project an average price target of $43.00, with a strong "Buy" rating based on 9 analysts. The company's expected revenue for the next …

FMR discloses 5.7% Upbound Group (UPBD) stake in Schedule 13G/A

FMR LLC and Abigail P. Johnson have reported a beneficial ownership of 3,312,579.34 shares, or 5.7% of Upbound Group Inc. common stock, via an Amendment No. 6 to a Schedule 13G filing. FMR LLC holds sole voting power over 3,312,091 shares and sole dispositive …

Upbound Group, Inc. $UPBD Shares Acquired by Sei Investments Co.

Sei Investments Co. significantly increased its stake in Upbound Group, Inc. by 249% in the first quarter, now owning 244,848 shares valued at $4.4 million. Despite the company beating Q1 earnings estimates with an EPS of $1.07 and revenue of $1.16 billion, its dividend …

Pacer Advisors Inc. Acquires Shares of 413,005 Upbound Group, Inc. $UPBD

Pacer Advisors Inc. acquired a new position of 413,005 shares in Upbound Group, Inc. (NASDAQ:UPBD) during the first quarter, valued at approximately $7.5 million. This gives Pacer Advisors a 0.71% stake in the company, which is 90.3% owned by institutional investors. Upbound Group recently …

Arrowstreet Capital Limited Partnership Buys New Holdings in Upstream Bio, Inc. $UPB

Upbound Group (NASDAQ:UPBD) Stock Rating Lowered by Zacks Research

Is UPBD a Value Opportunity or a Trap Amid Persistent Demand Risks?

Upbound Group, Inc. UPBD trades at a steep discount, but the low multiple reflects more than market neglect. Soft discretionary demand, uneven segment profitability and tighter underwriting are limiting near-term growth. The counterweight is meaningful. Cash generation improved sharply, liquidity remains ample and the …

Can UPBD Turn Brigit Growth and Acima Margin Gains Into a Rebound?

Upbound Group, Inc. UPBD delivered second-quarter 2026 results that were stable at the consolidated level but sharply divided by segment. Revenues increased 0.5% year over year to $1.16 billion, while adjusted EBITDA declined 4.6% to $127 million as softer consumer demand and higher costs …

Upstream Bio, Inc. (NASDAQ:UPB) Receives Average Recommendation of "Hold" from Analysts

Seven analysts currently covering Upstream Bio (NASDAQ:UPB) have given the company a consensus "Hold" rating, with an average 12-month price target of $33.17, significantly above its current trading price of $6.57. The clinical-stage biotech recently reported a quarterly loss of $0.75 per share, missing …

Upbound Group, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:UPBD) 2026-07-31

Upbound Group, Inc. (NASDAQ:UPBD) published its Q2 2026 earnings call presentation on July 31, 2026. The company reported an EPS of $1.07, beating estimates by $0.02, while revenue of $1.16 billion missed expectations by $780.86K. This article from SA Transcripts provides access to the …

Upbound Group stock rating cut to neutral by BTIG on leasing woes

BTIG has downgraded Upbound Group (NASDAQ: UPBD) to Neutral from Buy, removing its price target due to increased uncertainty in the company's estimates, particularly weakness in its core leasing business. While the company's second-quarter earnings and revenue surpassed expectations, challenges like softer volume in …

Upbound Group (NASDAQ: UPBD) grows H1 2026 earnings and operating cash flow

Upbound Group (NASDAQ: UPBD) reported increased earnings and operating cash flow for the first half of 2026. Total revenues reached $2,383.2 million, with net earnings rising to $57.4 million and operating cash flow to $294.0 million. The Brigit acquisition significantly contributed to subscription revenues, …

Upbound Group: Q2 Earnings Snapshot

This article provides a brief earnings snapshot for Upbound Group's Q2 performance. It is a very short piece, likely a placeholder or an automatically generated headline, with no detailed financial information available in the provided content.

Upbound Group, Inc. Revenue Breakdown – LSX:900457

Upbound Group, Inc. (LSX:900457) generated 4.00 billion EUR in revenue last year, with its top-performing segment, Acima, contributing 2.14 billion EUR. The United States was the largest regional contributor, accounting for 3.93 billion EUR of the company's revenue.

Press Release: Upbound Group, Inc. Reports Second Quarter 2026 Results

Upbound Group, Inc. has released its second-quarter results for 2026. The announcement provides financial data and performance metrics for the company during this period. Further details would be available within the complete press release document.

Upbound Group Inc reports results for the quarter ended June 30 - Earnings Summary

Upbound Group Inc. has released its earnings summary for the quarter that concluded on June 30. The article, primarily a news brief, indicates that the full details of these results are available from Reuters and other news sources on TradingView.

Earnings call transcript: Upbound tops Q2 2026 estimates but stock slips

Upbound Group Inc. exceeded Q2 2026 revenue and earnings estimates, yet its stock declined due to softer volumes in its Acima business, a cybersecurity-related fraud incident, and a cautious outlook. The company reported adjusted EPS of $1.07 and revenue of $1.2 billion, both surpassing …

(UPBD) Upbound Group, Inc. Expects Q3 Revenue Range $1.05B - $1.15B

Upbound Group, Inc. (UPBD) forecasts its third-quarter revenue to be in the range of $1.05 billion to $1.15 billion. This announcement follows the company's Q2 earnings report, which indicated a decline in non-GAAP earnings and an outlook that missed estimates for Q3. Investors are …